Figure 1 Total R&D Pipeline Size by Year 2001-2017
Figure 2 Pipeline by Development Phase
Figure 3 Clinical Phase Trends 2007-2017
Figure 4 Distribution of Likelihood of Approval Ratings for Pipeline Drugs in Phase II to Pre-registration
Table 1 Top 25 Pharma Companies by Size of Pipeline
Figure 5 Total Number of Companies with Active Pipelines 2001-2017
Figure 6 Distribution of R&D Companies by HQ Country/Region 2016 and 2017
Figure 7 The R&D Pipeline by Therapy Group
Table 2 Top 25 Therapeutic Categories
Table 3 Top 25 Diseases/Indications
Table 4 Top 25 Origins of Pipeline Drugs
Figure 8 Biological vs Non-biological Drugs as a Percentage of the Pipeline 1995-2017
Figure 9 Pipeline by Delivery Route 2016 & 2017
Table 5 Top 25 Mechanisms of Action (Pharmacologies)
Table 6 Top 25 Drug Protein Targets
Figure 10 Number of New Drug Protein Targets Identified by Pharmaprojects by Year
Figure 11 Rise in Numbers of Drugs Receiving Orphan Drug Status or an Expedited Review Designation 2013-2016